The dose

March 19, 2024

“Revolutionary Breakthroughs and Sky-High Achievements: Today’s Headlines Unveiled”

💫Daily Affirmation💫

“Today, I embrace the ever-evolving journey towards personal growth and understanding. I am open to the transformative experiences that guide me towards a deeper connection with myself and the world around me.”

Psychedelic Industry News:

Clearmind Medicine Inc. has achieved a significant breakthrough with its psychedelic treatment being granted divisional patent approval in China. This patent covers primary amine aminoindan compounds, which includes MEAI, Clearmind’s innovative psychedelic molecule. MEAI has shown potential in regulating binge behaviors and addiction, offering a new approach to combatting these issues.

Clearmind Medicine Inc. has recently made a significant advancement in the field of psychedelic therapy. Their innovative molecule, MEAI (5-methoxy-2-aminoindan), has been granted divisional patent approval in China1. This patent encompasses primary amine aminoindan compounds, a category that includes MEAI.

MEAI has been recognized for its potential to regulate binge behaviors and addiction, which could revolutionize the approach to treating these conditions. In pre-clinical studies over the past two years, MEAI has shown promising results in managing binge behaviors, addiction, and other mental health disorders2. This molecule is particularly noteworthy for its ability to reduce the desire to consume alcoholic beverages while providing a mild euphoric, alcohol-like experience2.

Clearmind’s MEAI-based treatment primarily targets Alcohol Use Disorder (AUD), a condition that ranges from mild to severe and is characterized by an individual’s inability to limit alcohol consumption despite adverse consequences2. The treatment could also be applicable to binge drinking, a dangerous addiction for some individuals2.

The divisional patent approval in China is a major milestone for Clearmind Medicine Inc., significantly expanding their intellectual property protection and establishing them as a leader in psychedelic-derived therapeutics. Their IP portfolio now includes 27 granted patents and 24 pending patent applications across 15 patent families, with patents granted in major jurisdictions like the US, Europe, China, and India2.

Cannabis Industry News:

SIVA Enterprises Inc. has published a landmark report on the “State of the Cannabis Industry,” which comes at a time of heightened anticipation for federal reform. This report is expected to provide valuable insights into the current landscape and future directions of the cannabis industry.

SIVA Enterprises Inc., a prominent consulting and advisory firm in the cannabis industry, has released a comprehensive report titled “State of the Cannabis Industry” at a pivotal moment when federal reform is highly anticipated1. This landmark report offers an in-depth analysis of the current state and future trajectory of the cannabis industry, addressing key issues and opportunities.

The report covers several critical topics, including:

• The implications of federal reform and the potential rescheduling of cannabis to a Schedule III substance.

• The existing regulatory environment and its complexities.

• A detailed examination of social equity programs and the reasons behind their shortcomings.

• The role of organized labor unions within the cannabis sector.

• The impact of Multi-State Operators (MSOs) on public markets.

• The disconnect between political promises and actions regarding cannabis policy.

• Direct messages to political parties and the Drug Enforcement Administration (DEA) concerning the industry’s future.

The “State of the Cannabis Industry Report” is positioned as a must-read for policymakers, business leaders, analysts, and advocates. It aims to provide clarity and a comprehensive perspective on the cannabis industry during a decisive period in its history. The report also highlights the significant potential of the cannabis industry as a driver of job creation and a source of substantial tax revenue.

SIVA Enterprises Inc. encourages all stakeholders to review the findings and participate in the ongoing conversation about the future of cannabis in America and beyond. The report is available for download on their website2.

Generative AI News:

Abridge has announced a collaboration with NVIDIA to deliver generative AI microservices to millions of clinicians and patients. This partnership will utilize NVIDIA’s compute resources and expertise to enhance clinical documentation with generative AI.Abridge, a leader in generative AI for clinical documentation, has announced a significant collaboration with NVIDIA. This partnership is set to deliver generative AI microservices to millions of clinicians and patients, leveraging NVIDIA’s advanced compute resources and expertise in deploying AI systems at scale1.

Here are some key points about this collaboration:

• Research Collaboration and Investment: NVIDIA is not only providing its technological resources but also investing in Abridge through NVentures, NVIDIA’s venture capital arm. This investment will help Abridge scale its multilingual clinical conversation platform across the entire U.S. healthcare system1.

• Technological Integration: Abridge will integrate NVIDIA’s foundation models and computing power to enhance its AI systems. These systems aim to structure vast amounts of unrecorded medical conversation data, thereby automating clerical work and providing insights for better care1.

• Efficiency and Scale: The collaboration is expected to bring methodological breakthroughs and deploy computing power intelligently. This will support Abridge’s rapid adoption across the U.S. and potentially on an international scale1.

• AI-Powered Clinical Documentation: The goal is to transform raw audio from medical conversations into meticulous documentation. This involves seamless integration of various AI technologies, including language identification, transcription, alignment, and diarization, all within seconds1.

• NVIDIA’s NIM Inference Microservices: Abridge’s deep learning stack will be powered by NVIDIA NIM inference microservices, part of the NVIDIA AI Enterprise software platform. This technology is built on NVIDIA TensorRT-LLM and is designed to enable AI inferencing at scale, reducing latency from minutes to seconds and saving clinicians hours1.

This collaboration is poised to revolutionize clinical documentation, making it more efficient and accessible. It’s a step forward in the application of generative AI in healthcare, with the potential to impact the lives of clinicians and patients positively.

Space Exploration News:

SpaceX has successfully launched a Falcon 9 rocket carrying 22 Starlink satellites from Vandenberg Space Force Base. This marks another milestone for SpaceX as it continues to expand its Starlink internet satellite constellation.SpaceX has achieved another significant milestone in its Starlink project with the successful launch of a Falcon 9 rocket. This launch, which took place from Vandenberg Space Force Base, carried 22 Starlink satellites into orbit1. Here are some expanded details about this event:

• Launch Details: The Falcon 9 rocket lifted off during a nearly four-hour window that opened at 10:28 p.m. EDT on March 181. This was part of SpaceX’s ongoing efforts to expand the Starlink broadband megaconstellation, which aims to provide global internet coverage.

• Rocket and Satellite Details: The first stage of the Falcon 9 rocket, making its 10th flight, successfully landed on the droneship “Of Course I Still Love You” stationed in the Pacific Ocean1. The 22 Starlink satellites were deployed into low Earth orbit approximately 62.5 minutes after liftoff1.

• Starlink Constellation: With this launch, SpaceX continues to build out its Starlink broadband megaconstellation. As of the latest updates, the constellation consists of more than 5,500 satellites1. SpaceX has conducted several launches dedicated to the Starlink project, significantly increasing the number of satellites in orbit.

• SpaceX’s 2024 Milestones: This launch is part of SpaceX’s ambitious schedule for 2024, which includes numerous operational missions and test flights. Notably, SpaceX conducted a high-profile test flight of its Starship megarocket earlier in the year, marking the third test mission for the spacecraft designed to help humanity settle the moon and Mars1.

Mental Health News:

A new study has debunked the myth that venting anger is an effective way to reduce rage. Instead, stress-reducing techniques like deep breathing, mindfulness, meditation, and yoga are found to be much more effective in managing anger.The recent study on anger management has provided new insights into the effectiveness of various techniques for reducing rage. Contrary to the popular belief that venting anger is beneficial, the study has found that it does not decrease anger levels. In fact, expressing anger may even be counterproductive, as it can increase physiological arousal and, consequently, feelings of anger1.

Here are some key findings from the study:

• Venting Is Ineffective: The study, which analyzed over 150 studies involving more than 10,000 participants, concluded that venting, such as grumbling to others, does not reduce anger. While it might provide temporary relief, it does not diminish the overall feeling of rage1.

• Stress-Reducing Techniques Work Better: Techniques that reduce stress and physiological arousal, such as deep breathing, mindfulness, meditation, and yoga, have been shown to be more effective in managing anger2. These activities help to lower the body’s fight-or-flight response, which is often heightened during anger.

• Physical Arousal and Anger: Activities that increase physical arousal, like jogging, were found to have no effect on reducing anger, and in some cases, they made it worse. The study emphasizes the importance of engaging in activities that decrease arousal levels to effectively manage anger2.

• Catharsis Theory Debunked: The study challenges the catharsis theory, which suggests that expressing anger is a healthy way to release it. The findings indicate that there is no scientific evidence to support this theory, and that engaging in arousal-decreasing activities is a better strategy1.

The study’s implications are significant, as they suggest a shift in how we approach anger management. Instead of encouraging people to vent their frustrations, it may be more beneficial to promote stress-reducing practices that can help individuals calm down and handle their emotions more constructively.